Secondary malignancies across the age spectrum.

Andrea K Ng, Lisa B Kenney, Ethel S Gilbert, Lois B Travis
Author Information
  1. Andrea K Ng: Department of Radiation Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ang@lroc.harvard.edu

Abstract

Development of a second malignancy is one of the most serious late effects in survivors of both childhood and adult-onset cancers. Patterns of second malignancy risk across the age spectrum can differ in terms of the types of second malignancies observed, magnitude of the risks, the latency period, associated risk factors, and modifying influences. Potential explanations for the varying risk patterns by age include differences in susceptibility of individual tissue/organ to carcinogenesis based on stage of development and level of tissue maturity, microenvironment, attained age, and lifestyle factors. A thorough understanding of these differences is essential when considering treatment modifications in newly diagnosed cancer patients who are aimed at reducing the risk of second malignancy and other late effects without compromising cure. Moreover, an understanding of the variations in second cancer risk according to age at treatment is important in customizing patient follow-up.

References

  1. N Engl J Med. 1986 May 8;314(19):1201-7 [PMID: 3702916]
  2. J Clin Oncol. 2006 Jan 20;24(3):476-83 [PMID: 16421424]
  3. J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [PMID: 9747868]
  4. J Clin Oncol. 2009 May 10;27(14):2356-62 [PMID: 19255307]
  5. Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):24-33 [PMID: 18722263]
  6. Blood. 2009 Feb 12;113(7):1408-11 [PMID: 18974371]
  7. J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [PMID: 8133536]
  8. Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):359-63 [PMID: 17379448]
  9. J Clin Oncol. 2000 Feb;18(3):498-509 [PMID: 10653865]
  10. Br J Cancer. 1986 Sep;54(3):483-92 [PMID: 3756084]
  11. J Clin Oncol. 2008 Jan 20;26(3):392-8 [PMID: 18202415]
  12. Eur J Haematol Suppl. 2005 Jul;(66):68-76 [PMID: 16007872]
  13. N Engl J Med. 1991 Nov 7;325(19):1330-6 [PMID: 1922234]
  14. J Clin Oncol. 2009 Jan 1;27(1):52-60 [PMID: 19047296]
  15. Br J Cancer. 2003 Sep 1;89(5):840-6 [PMID: 12942115]
  16. Blood. 2005 May 15;105(10):3802-11 [PMID: 15687239]
  17. J Clin Oncol. 2000 Apr;18(7):1492-9 [PMID: 10735897]
  18. Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):1195-203 [PMID: 15990025]
  19. Radiat Res. 2003 Feb;159(2):161-73 [PMID: 12537521]
  20. Radiat Res. 2002 Aug;158(2):220-35 [PMID: 12105993]
  21. AMA Arch Derm Syphilol. 1952 Feb;65(2):123-9 [PMID: 14884692]
  22. Cancer. 2001 Jul 1;92(1):172-80 [PMID: 11443624]
  23. J Natl Cancer Inst. 2007 Jan 3;99(1):24-31 [PMID: 17202110]
  24. J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [PMID: 11309438]
  25. J Clin Oncol. 2009 Aug 20;27(24):3901-7 [PMID: 19620485]
  26. J Clin Oncol. 2007 Apr 20;25(12):1489-97 [PMID: 17372278]
  27. Med Pediatr Oncol. 1998 Aug;31(2):91-5 [PMID: 9680933]
  28. J Clin Oncol. 2000 Feb;18(3):487-97 [PMID: 10653864]
  29. J Clin Oncol. 2001 Jul 1;19(13):3173-81 [PMID: 11432883]
  30. J Clin Oncol. 2005 Jan 1;23(1):197-204 [PMID: 15625374]
  31. Front Radiat Ther Oncol. 2007;40:253-271 [PMID: 17641514]
  32. Cancer. 2000 Jan 15;88(2):398-406 [PMID: 10640974]
  33. Br J Cancer. 2004 Nov 29;91(11):1905-10 [PMID: 15534607]
  34. Leukemia. 1995 Dec;9(12):1990-6 [PMID: 8609707]
  35. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):661-8 [PMID: 16545920]
  36. Ann Intern Med. 2004 Oct 19;141(8):590-7 [PMID: 15492338]
  37. J Clin Endocrinol Metab. 1993 Aug;77(2):362-9 [PMID: 8345040]
  38. Lancet. 2005 May 14-20;365(9472):1687-717 [PMID: 15894097]
  39. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1021-30 [PMID: 18556141]
  40. J Clin Oncol. 1993 Mar;11(3):485-90 [PMID: 8383191]
  41. J Clin Oncol. 2005 Apr 1;23(10):2272-9 [PMID: 15800318]
  42. Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1038-45 [PMID: 12829139]
  43. J Natl Cancer Inst. 2005 Sep 21;97(18):1354-65 [PMID: 16174857]
  44. J Clin Endocrinol Metab. 2000 Sep;85(9):3227-32 [PMID: 10999813]
  45. Cancer Res. 1991 Jun 1;51(11):2885-8 [PMID: 1851664]
  46. Cancer. 2003 May 15;97(10):2397-403 [PMID: 12733137]
  47. JAMA. 2007 Mar 21;297(11):1207-15 [PMID: 17374815]
  48. Oncologist. 2007 Jan;12(1):20-37 [PMID: 17227898]
  49. Dermatology. 2004;209(3):175-6 [PMID: 15459528]
  50. Cancer. 1993 May 15;71(10):3054-7 [PMID: 8490833]
  51. Radiat Res. 2006 Oct;166(4):618-28 [PMID: 17007558]
  52. Lancet. 1999 Jul 3;354(9172):34-9 [PMID: 10406363]
  53. N Engl J Med. 1992 Jun 25;326(26):1745-51 [PMID: 1594016]
  54. N Engl J Med. 1987 Sep 3;317(10):588-93 [PMID: 3475572]
  55. J Clin Oncol. 2008 Dec 1;26(34):5561-8 [PMID: 18854572]
  56. J Clin Oncol. 2003 Sep 15;21(18):3431-9 [PMID: 12885835]
  57. Cancer. 2005 Aug 15;104(4):856-63 [PMID: 15981282]
  58. Blood. 2003 Jul 1;102(1):43-52 [PMID: 12623843]
  59. J Natl Cancer Inst. 2008 Dec 17;100(24):1771-9 [PMID: 19066271]
  60. J Natl Cancer Inst. 2005 Jul 20;97(14):1056-66 [PMID: 16030303]
  61. Radiother Oncol. 2002 Dec;65(3):145-51 [PMID: 12464442]
  62. J Clin Oncol. 2002 Apr 15;20(8):2101-8 [PMID: 11956271]
  63. Lancet. 2005 Dec 17;366(9503):2087-106 [PMID: 16360786]
  64. J Clin Oncol. 1998 Dec;16(12):3761-7 [PMID: 9850019]
  65. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1313-9 [PMID: 16997501]
  66. J Clin Oncol. 2001 Jul 1;19(13):3163-72 [PMID: 11432882]
  67. Eur J Cancer. 2006 Nov;42(16):2757-64 [PMID: 16965909]
  68. Br J Cancer. 2004 Aug 31;91(5):868-72 [PMID: 15292931]
  69. Cancer. 2003 Mar 15;97(6):1404-11 [PMID: 12627503]
  70. Cancer. 2003 Oct 1;98(7):1457-64 [PMID: 14508833]
  71. Am J Epidemiol. 2005 Feb 15;161(4):330-7 [PMID: 15692076]
  72. J Natl Cancer Inst. 2004 Mar 3;96(5):357-63 [PMID: 14996857]
  73. Eur J Cancer. 1998 Dec;34(13):2068-75 [PMID: 10070313]
  74. Strahlenther Onkol. 2007 Feb;183(2):57-62 [PMID: 17294108]
  75. Cancer. 2006 Sep 1;107(5):991-8 [PMID: 16878323]
  76. J Natl Cancer Inst. 2006 Jan 4;98(1):15-25 [PMID: 16391368]
  77. J Natl Cancer Inst. 1996 Mar 6;88(5):270-8 [PMID: 8614005]
  78. J Clin Oncol. 2005 Jun 20;23(18):4179-91 [PMID: 15961765]
  79. Br J Cancer. 2008 Mar 11;98(5):870-4 [PMID: 18268495]
  80. Blood. 2000 May 1;95(9):2770-5 [PMID: 10779419]
  81. J Clin Oncol. 1994 May;12(5):1063-73 [PMID: 8164031]
  82. J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [PMID: 17077355]
  83. Dermatol Surg. 2007 Jun;33(6):749-55 [PMID: 17550458]
  84. Int J Cancer. 1999 Dec 10;83(6):860-3 [PMID: 10597212]
  85. J Natl Cancer Inst. 2002 Feb 6;94(3):182-92 [PMID: 11830608]
  86. N Engl J Med. 1992 Mar 19;326(12):781-5 [PMID: 1538720]
  87. Lancet. 2005 Jun 11-17;365(9476):2014-23 [PMID: 15950715]
  88. Blood. 2002 Jun 15;99(12):4257-64 [PMID: 12036851]
  89. Lancet. 2000 Sep 9;356(9233):881-7 [PMID: 11036892]
  90. BMJ. 1992 Apr 11;304(6832):951-8 [PMID: 1581717]
  91. J Natl Cancer Inst. 1995 Jan 4;87(1):60-1 [PMID: 7666469]
  92. J Clin Oncol. 2002 Aug 15;20(16):3484-94 [PMID: 12177110]
  93. Cancer. 2003 Oct 1;98(7):1362-8 [PMID: 14508821]
  94. Breast Cancer Res Treat. 2007 Dec;106(3):439-51 [PMID: 17277968]
  95. Lancet. 1991 Aug 10;338(8763):359-63 [PMID: 1713639]
  96. J Natl Cancer Inst. 2005 Oct 5;97(19):1428-37 [PMID: 16204692]
  97. J Clin Oncol. 2003 Dec 1;21(23):4386-94 [PMID: 14645429]
  98. J Urol. 2005 Jul;174(1):107-10; discussion 110-1 [PMID: 15947588]
  99. J Clin Oncol. 1996 May;14(5):1442-6 [PMID: 8622057]
  100. J Natl Cancer Inst. 2003 Jul 2;95(13):971-80 [PMID: 12837833]
  101. J Clin Oncol. 2003 Apr 1;21(7):1195-204 [PMID: 12663705]
  102. N Engl J Med. 1991 Dec 12;325(24):1682-7 [PMID: 1944468]
  103. Ann Oncol. 2005 Aug;16(8):1343-51 [PMID: 15905306]
  104. Cancer. 1994 Mar 15;73(6):1615-20 [PMID: 8156488]
  105. J Clin Oncol. 2001 Mar 15;19(6):1610-8 [PMID: 11250989]
  106. JAMA. 2003 Jul 23;290(4):465-75 [PMID: 12876089]
  107. JAMA. 1997 Oct 15;278(15):1262-7 [PMID: 9333268]
  108. J Clin Oncol. 1999 Jun;17(6):1829-37 [PMID: 10561222]
  109. Ann Intern Med. 2002 Mar 19;136(6):463-70 [PMID: 11900499]
  110. Pediatr Blood Cancer. 2004 Jun;42(7):563-73 [PMID: 15127410]
  111. N Engl J Med. 2007 Nov 8;357(19):1916-27 [PMID: 17989384]
  112. J Natl Cancer Inst. 2000 Jul 19;92(14):1165-71 [PMID: 10904090]
  113. Br J Cancer. 2007 Jul 2;97(1):115-7 [PMID: 17519906]
  114. Lancet. 1993 Jun 5;341(8858):1428-32 [PMID: 8099139]
  115. Blood. 2002 Sep 15;100(6):1989-96 [PMID: 12200357]
  116. Pediatr Blood Cancer. 2005 Jul;45(1):25-31 [PMID: 15795880]
  117. Cancer. 2007 Jul 1;110(1):31-7 [PMID: 17510927]

Grants

  1. ZIA CP010131/Intramural NIH HHS
  2. ZIA CP010131-17/Intramural NIH HHS

MeSH Term

Adult
Age Distribution
Aging
Breast Neoplasms
Child
Child, Preschool
Female
Genital Neoplasms, Male
Hodgkin Disease
Humans
Incidence
Life Style
Lung Neoplasms
Male
Neoplasms, Second Primary
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Retinoblastoma
Risk Factors
Thyroid Neoplasms

Word Cloud

Created with Highcharts 10.0.0secondriskagemalignancylateeffectsacrossspectrummalignanciesfactorsdifferencesunderstandingtreatmentcancerDevelopmentoneserioussurvivorschildhoodadult-onsetcancersPatternscandiffertermstypesobservedmagnituderiskslatencyperiodassociatedmodifyinginfluencesPotentialexplanationsvaryingpatternsincludesusceptibilityindividualtissue/organcarcinogenesisbasedstagedevelopmentleveltissuematuritymicroenvironmentattainedlifestylethoroughessentialconsideringmodificationsnewlydiagnosedpatientsaimedreducingwithoutcompromisingcureMoreovervariationsaccordingimportantcustomizingpatientfollow-upSecondary

Similar Articles

Cited By